688075 安旭生物
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入325,287-19.34%540,698503,3576,165,8841,589,279
减:营业总成本392,9040.71%502,119442,7091,967,504712,620
    其中:营业成本192,490-17.55%329,275290,4451,554,904549,181
               财务费用27,771319.33%(38,377)(70,937)(533,589)23,085
               资产减值损失----(12,778)(23,966)(763,897)(11,170)
公允价值变动收益32,45327.80%63,427(54,802)(9,421)102
投资收益89,8652.61%118,212140,10758,41811,840
    其中:对联营企业和合营企业的投资收益------------
营业利润58,752-59.20%207,583167,4843,528,837865,073
利润总额64,237-55.39%210,640143,8173,519,508864,620
减:所得税费用(71)-100.86%18,4032,852475,336126,094
净利润64,308-52.63%192,237140,9653,044,172738,526
减:非控股权益(51)42.71%(58)(589)(502)--
股东净利润64,359-52.60%192,295141,5543,044,673738,526

市场价值指针
每股收益 (元) *0.510-52.34%1.5101.11023.95010.550
每股派息 (元) *----1.2000.4005.0003.880
每股净资产 (元) *40.6240.22%40.94740.20659.73042.497
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容